

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 June 2025 (19.06.2025)



(10) International Publication Number
WO 2025/125513 A1

(51) International Patent Classification:

A61K 31/438 (2006.01) *A61P 13/12* (2006.01)
A61K 31/7032 (2006.01) *A61K 31/7042* (2006.01)
A61P 9/12 (2006.01) *A61K 31/7048* (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

(21) International Application Number:

PCT/EP2024/086083

(22) International Filing Date:

12 December 2024 (12.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/610,570 15 December 2023 (15.12.2023) US

Published:

— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(71) Applicant: **ASTRAZENECA IRELAND LIMITED**

[IE/IE]; College Business & Technology Park, Blanchardstown Road North, Dublin 15, Dublin, D15 R925 (IE).

(72) Inventors: **LITTLE, Dustin**; ASTRAZENECA PHARMACEUTICALS LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **ROSSERT, Jerome**; ASTRAZENECA PHARMACEUTICALS LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **MYTE, Robin**; ASTRAZENECA AB, 151 85 Södertälje (SE).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Eastbrook House Shaftesbury Road, Cambridge, Cambridgeshire CB2 8BF (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: SGLT2 INHIBITORS AND BAXDROSTAT FOR TREATING CHRONIC KIDNEY DISEASE AND HYPERTENSION

(57) Abstract: The disclosure provides methods of treating chronic kidney disease (CKD) and hypertension in a patient in need thereof, the method comprising administering to the patient a combination comprising baxdrostat or a pharmaceutically acceptable salt thereof and a sodium-glucose co-transporter 2 (SGLT2) inhibitor.

WO 2025/125513 A1